Proteogenomics reveals new target for beating drug resistance in acute myeloid leukemia

Doctors have nearly a dozen new targeted drugs to treat patients with acute myeloid leukemia, or AML, yet three of four patients still die within five years.

Related Keywords

Oregon ,United States ,American ,Marina Gritsenko ,Kevin Watanabe Smith ,Paul Daisy Soros ,Joshua Hansen ,Karl Weitz ,Tao Liu ,Paul Piehowski ,Jason Mcdermott ,Elie Traer ,Sunil Joshi ,Sara Gosline ,Kanupriya Agarwal ,Cristina Tognon ,James Pino ,Chelsea Hutchinson ,Jeff Tyner ,Brian Druker ,Michael Nestor ,Karin Rodland ,Knight Cancer Institute ,Doe Pacific Northwest National Laboratory ,National Cancer Institute ,School Of Medicine ,Blood Institute ,Pacific Northwest Biomedical Innovation Co ,Research Program ,Alex Lemonade Stand Foundation ,Department Of Energy Pacific Northwest National Laboratory ,Druker Laboratory ,Evansmds Foundation ,American Cancer Society ,Oregon Health Science University ,Scholar Foundation ,National Heart ,Pacific Northwest National ,Cell Reports Medicine ,Pacific Northwest National Laboratory ,Oregon Health ,Knight Cancer ,Annual Reviews ,Camilo Posso ,Jamie Moon ,Chelsea Hutchinson Bunch ,Nicola Long ,Cancer Clinical Proteomics Research ,Daisy Soros Fellowship ,Lemonade Stand ,Cancer ,Acute Myeloid Leukemia ,Flood ,Rain ,Fell ,Drugs ,Genes ,Laboratory ,Leukemia ,Machine Learning ,Medicine ,Myeloid Leukemia ,Protein ,Roteomics ,Research ,Humor ,